Compare Citius Pharmaceuticals Inc (CTXR) vs e l f Beauty Inc (ELF) Price & Performance

CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.

Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.

ELF Beauty trades at $75.10, down 2.15% on the day, with a bullish technical signal from moving averages. The company reported strong revenue of $1.31 billion in 2025 and has beaten earnings estimates for three consecutive quarters. Recent news highlights brand expansion and a 32% stock jump in June 2026, though growth is transitioning as the core brand softens.

The outlook is mixed: analyst consensus is evenly split between Buy and Hold, with a $74.42 price target near the current price. Upside potential exists from skincare and international expansion, but risks include cost pressures, tariff exposure, and the need to sustain double-digit sales growth amid competitive dynamics.